BillionToOne is positioning itself not just as a diagnostics player, but as a category-defining healthcare company with disruptive technology and accelerating financial performance. Investors will be weighing the promise of its breakthrough platform and growing test adoption against the risks of operating in a highly competitive and capital-intensive diagnostics market.

Navan, Inc. (NASDAQ: NAVN) has officially filed to go public, bringing one of Silicon Valley’s most closely watched AI-powered travel and expense platforms to the Nasdaq Global Select Market. The company is offering 30 million shares, with another 6.9 million shares coming from selling stockholders, at an expected price range of $24 to $26. At the $25 midpoint, Navan will command a market capitalization of approximately $6.21 billion on 248.2 million shares outstanding. The company itself expects to raise about $750 million in proceeds, while the total deal size reaches $923 million, or $1.06 billion if underwriters fully exercise their overallotment option. Leading underwriters of the deal are Goldman Sachs and Citigroup, with support from Jefferies, Mizuho, and Morgan Stanley among others.